Alto Neuroscience, Inc.

NYSE:ANRO

Biotechnology

Healthcare
$25.91 +1.84%

+$0.40 today

Market cap
$1.04B
Beta
1.25
P/E (TTM)
-9.8
EPS (TTM)
-$2.26
52W Low $2.15High $28.44

Volume 0.99M

Average 0.34M

ANRO Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Alto Neuroscience, Inc.NYSE: ANRO

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 75.0% from a year ago

Total equity stood at $243.37M at the end of Q1 FY2026, up 75.0% from a year earlier and up 61.0% from the prior quarter.

Context

  • Total equity amounted to 88.1% of total assets at the end of Q1 FY2026, up 7.2 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +75.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$243.37M+61.0% QoQ
Last fiscal yearDec 2025
$151.14M-0.2% YoY
Year agoMar 2025
$139.1M+75.0% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+75.0%——
1 year-0.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
151.14M USD
Year-over-year change
-0.2%

Total Equity vs competitors

How ANRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +75.0% is the 3rd highest of 11, against a peer median of +2.2%.
  • Total equity amounts to 88.1% of total assets for ANRO, versus a peer median of 64.5%.
ANRO Competitors
Total Equity for ANRO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AMRNAmarin Corporation plcMar 2026$449.41M USD-5.1%-8.3%69.6%
CTNMContineum Therapeutics, Inc. Class A Common StockMar 2026$250.04M USD+35.3%+88.0%95.7%
ANROAlto Neuroscience, Inc.Mar 2026$243.37M USD+75.0%—88.1%
DBVTDBV Technologies S.A.Mar 2026$207.9M USD+7136.3%-4.6%78.0%
LRMRLarimar Therapeutics, Inc.Mar 2026$158.03M USD+9.5%-11.0%75.8%
KRROKorro Bio, Inc.Mar 2026$119.63M USD-13.9%—65.2%
DRTSAlpha Tau Medical Ltd.Mar 2026$69.35M USD+23.1%-10.0%63.8%
CLLSCellectis S.A.Mar 2026$59.92M USD-48.4%-15.5%20.7%
SLNSilence Therapeutics plcMar 2026$49.4M USD+143.8%+41.3%42.9%
ALDXAldeyra Therapeutics, Inc.Mar 2026$42.16M USD-33.7%-33.6%63.4%
ACIUAC Immune S.A.Mar 2026CHF 31.53M CHF-66.7%-35.7%22.9%
Peer median (excluding ANRO) —+2.2%-10.0%64.5%

Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents25.71M48.34M82.55M168.23M176.48M
Short-term Investments00000
Net Receivables1.74M546K8K00
Inventory00000
Other Current Assets002.31M30K1.23M
Total Current Assets27.68M49.22M85.39M169.34M177.72M
Property, Plant & Equipment (Net)1.06M1.58M1.11M7.7M6.13M
Goodwill00000
Intangible Assets00000
Long-term Investments000500K500K
Tax Assets00000
Other Non-current Assets50K55K131K4K338K
Total Non-current Assets1.11M1.63M1.24M8.21M6.97M
Total Assets28.79M50.85M86.63M177.54M184.69M
Account Payables600K1.61M1.07M1.58M1.88M
Short-term Debt0283K00585K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.19M3.54M008.86M
Total Current Liabilities1.81M5.56M5.61M10.01M11.33M
Long-term Debt38.16M81.7M9.86M11.56M3.82M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.3M1.88M142.83M018.4M
Total Non-current Liabilities39.46M83.7M152.69M16.07M22.22M
Total Liabilities41.27M89.26M158.3M26.08M33.55M
Common Stock1K1K03K3K
Retained Earnings(12.95M)(40.66M)(76.97M)(138.4M)(201.63M)
Accumulated OCI(22K)(46K)(79K)(101K)22K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(12.48M)(38.41M)(71.67M)151.46M151.14M
Total Debt38.16M82.11M9.99M16.94M4.41M
Net Debt12.46M33.76M(72.56M)(151.29M)(172.08M)

Alto Neuroscience, Inc.

NYSE:ANRO

Intrinsic Alpha fair value

Locked

Current Price

$25.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.